Axonics® receives fda approval for third-generation implantable neurostimulator

Irvine, calif.--(business wire)--axonics modulation technologies, inc. (nasdaq: axnx), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (snm) devices for the treatment of urinary and bowel dysfunction, has received pma supplement approval from the u.s. food & drug administration (fda) for its third-generation implantable neurostimulator (ins). this marks the sixth fda approval axonics has received for a significant product innov
AXNX Ratings Summary
AXNX Quant Ranking